DA
David Amsellem Piper Sandler Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Supernus Pharmaceuticals
SUPN
$2.58B
| $46 | $40 |
13%
downside
| Neutral | 7 days ago |
|
2
Amgen
AMGN
$153B
| $283.64 | $342 |
21%
upside
| Overweight | 11 days ago |
|
3
Biogen
BIIB
$20.6B
| $140.67 | $118 |
16%
downside
| Neutral | 22 days ago |
|
4
AbbVie
ABBV
$375B
| $212.56 | $231 |
9%
upside
| Overweight | 24 days ago |
|
5
Amphastar Pharmaceuticals
AMPH
$1.37B
| $29.42 | $25 |
15%
downside
| Neutral | 28 days ago |
|
6
Corcept Therapeutics
CORT
$7.31B
| $69.36 | $121 |
74%
upside
| Overweight | 1 month ago |
|
7
Neurocrine Biosciences
NBIX
$14.3B
| $144.10 | $175 |
21%
upside
| Overweight | 1 month ago |
|
8
Organon & Co
OGN
$2.7B
| $10.38 | $18 |
73%
upside
| Overweight | 3 months ago |
|
9
Collegium Pharmaceutical
COLL
$1.21B
| $38.32 | $37 |
3%
downside
| Neutral | 3 months ago |
|
10
Jazz Pharmaceuticals
JAZZ
$7.86B
| $129.50 | $147 |
14%
upside
| Overweight | 4 months ago |
|
11
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $65 |
38%
upside
| Overweight | 4 months ago |
|
12
Xeris Biopharma Holdings
XERS
$1.27B
| $7.85 | $4 |
49%
downside
| Neutral | 6 months ago |
|
13
Indivior
INDV
$3.12B
| $24.98 | $13 |
48%
downside
| Overweight | 6 months ago |
|
14
Viatris
VTRS
$12.2B
| $10.50 | $10 |
5%
downside
| Neutral | 6 months ago |
|
15
Teva Pharmaceuticals
TEVA
$21.7B
| $18.95 | $30 |
58%
upside
| Overweight | 7 months ago |
|
|
AVDL
16
Avadel Pharmaceuticals
AVDL
$1.53B
| $15.76 | $13 |
18%
downside
| Overweight | 7 months ago |
|
17
Amneal Pharmaceuticals
AMRX
$3.02B
| $9.62 | $11 |
14%
upside
| Overweight | 9 months ago |
|
18
Alkermes
ALKS
$4.94B
| $29.94 | $37 |
24%
upside
| Overweight | 10 months ago |
|
19
ANI Pharmaceuticals
ANIP
$2.07B
| $95.35 | $68 |
29%
downside
| Overweight | 10 months ago |
|
20
Bausch Health
BHC
$2.72B
| $7.35 | $3 |
59%
downside
| Underweight | 1 year ago |
|
21
Pacira BioSciences
PCRX
$1.19B
| $26.45 | $42 |
59%
upside
| Overweight | 1 year ago |
|
22
Aquestive Therapeutics
AQST
$656M
| $5.42 | $10 |
85%
upside
| Overweight | 1 year ago |
|
23
Axsome Therapeutics
AXSM
$6.25B
| $125.17 | $113 |
10%
downside
| Overweight | 1 year ago |
|
24
Harmony Biosciences
HRMY
$2.07B
| $35.99 | $42 |
17%
upside
| Overweight | 1 year ago |
|